about
PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivoMacrophage migration inhibitory factor involvement in breast cancer (Review)MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cellsMIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development.Antibody-based therapies in multiple myelomaNovel targeted therapies for mantle cell lymphomaTarget Therapy in Hematological Malignances: New Monoclonal Antibodies.An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma.CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas.CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic review.Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach.Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.Expression of CD74 in bladder cancer and its suppression in association with cancer proliferation, invasion and angiogenesis in HT-1376 cells.
P2860
Q24317781-4DE9A007-2C2B-42AD-BA63-53BF283E0C3BQ26786136-700D0A10-1E93-40AC-B1E5-5EEC7122C314Q30836134-859E4CC8-E408-4060-85CC-32A63A5FE778Q33621610-63875933-915C-4B74-BB07-6CAFAD1053EEQ34193553-354F23D1-24D6-4B58-8694-86F3A68B6C5EQ34543093-4747318B-BD5E-4785-9EAE-4E8F44EE3B73Q35431150-B6D7D4D9-57A2-415F-83EF-7C2F0DDA72E5Q35889841-7B6F9CE3-D0DB-423B-9A9A-4A1A24D8C012Q36979140-F9D9E2D1-9F6C-45C1-81D3-4C7EEF68806FQ37029273-0C013AC8-3955-4DFF-9706-5E23BF2B0B40Q37786616-2CC16AB6-F837-4ED7-8DB5-B74490193B92Q37826194-B5196B0F-FE04-4C3A-8CB2-82E7B9A68AA2Q38002982-DB91D83B-B284-4BCB-B2CD-564D70B1023AQ38090691-A4350FD1-4CE8-44A7-8619-D000280309AEQ38737970-6B9DE00D-578A-4E3F-A19F-2B4441358C7FQ38961107-5A3FC33E-FD11-497B-98C1-CF2E7134F823Q44476535-B54526E5-07FE-44B4-83A5-5978B850D700Q47221234-F12D1BD2-1BD6-41F7-AE57-0B09BF7D7145Q47894776-100D6C12-7E0C-4B01-9ED7-4961B64149B6Q52715769-0EF3CDFE-954E-4CD9-A1BB-7FDB8E29B9F6Q54941924-B434458F-D87F-48F8-B43E-4325DF334684Q55280756-2ECFBA73-3286-4F34-8B5E-0E7C9C81140E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Milatuzumab - a promising new immunotherapeutic agent.
@en
Milatuzumab - a promising new immunotherapeutic agent.
@nl
type
label
Milatuzumab - a promising new immunotherapeutic agent.
@en
Milatuzumab - a promising new immunotherapeutic agent.
@nl
prefLabel
Milatuzumab - a promising new immunotherapeutic agent.
@en
Milatuzumab - a promising new immunotherapeutic agent.
@nl
P2860
P1476
Milatuzumab - a promising new immunotherapeutic agent
@en
P2093
Felipe Samaniego
Rong-Hua Tao
P2860
P304
P356
10.1517/13543780903463854
P407
P50
P577
2010-01-01T00:00:00Z